Viatris Q3 Adj. EPS $0.71 Beats $0.64 Estimate, Sales $3.749B Miss $3.786B Estimate
Share
Why It Matters
Viatris made more profit per share than expected this quarter. But they sold less medicine than people thought they would.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.